Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06549816
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳Jiangsu Province Hospital, Nanjing, China
🇨🇳Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China
A Study of PF-08052666/SGN-MesoC2 in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT06466187
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT06362590
A Safety Study of SGN-35C in Adults With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT06254495
- Locations
- 🇩🇰
Rigshospitalet University Hospital of Copenhagen, Copenhagen, Other, Denmark
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego / Moores Cancer Center, La Jolla, California, United States
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT06157892
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Other, Italy
🇺🇸Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
🇺🇸Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States
A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 410
- Registration Number
- NCT06131840
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Other, Netherlands
🇺🇸Florida Cancer Specialists - Lake Nona, Orlando, Florida, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Safety Study of SGN-35T in Adults With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06120504
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Stanford Cancer Center / Blood and Marrow Transplant Program, Palo Alto, California, United States
🇺🇸University of Miami, Miami, Florida, United States
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT06012435
- Locations
- 🇨🇭
Inselspital, Bern, Other, Switzerland
🇫🇷Hospital Center De Cornouaille, Quimper Cedex, Other, France
🇫🇷Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou, Rennes, Other, France
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT06003231
- Locations
- 🇮🇹
Fondazione IRCCS San Gerardo dei Tintori, Monza, Other, Italy
🇬🇧Guy's and St Thomas' NHS Foundation, London, Other, United Kingdom
🇺🇸Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States
A Study of SGN-EGFRd2 in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT05983133
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology & Oncology, Santa Monica, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States